Skip to main content
Premium Trial:

Request an Annual Quote

Synthetic Genomics, Gen9 Ink Licensing Agreement

NEW YORK (GenomeWeb) – Synthetic Genomics and Gen9 today announced a licensing deal. 

The agreement provides Gen9 a non-exclusive worldwide license to SGI's Febit intellectual property estate. The technology, purchased in 2012 by SGI from Febit Holding, comprises three families of patents and patent applications covering synthetic genomic methods. They include methods for highly parallelized, low-cost oligonucleotide synthesis and retrieval of sequence-validated DNA. SGI has been using the technology to develop gene synthesis applications. 

Financial and other terms of the deal were not disclosed. 

"We see great value in the Febit IP for companies like Gen9 to increase efficiencies in their manufacturing platforms," Nathan Wood, Synthetic Genomics' senior VP and president of SGI-DNA, Reagents and Instruments, said in a statement.